Eli Lilly (LLY) Receivables - Net (2009 - 2026)

Eli Lilly has reported Receivables - Net for 18 years, with the latest figure at $18.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 53.11% year-over-year to $18.4 billion; the trailing twelve-month figure through Mar 2026 stood at $18.4 billion (up 53.11% YoY), and the FY2025 full-year result was $17.8 billion, up 61.37% from the prior year.
• Receivables - Net for Q1 2026 stood at $18.4 billion, up from $17.8 billion in the prior quarter.
• The five-year high for Receivables - Net was $18.4 billion in Q1 2026, with the low at $6.3 billion in Q1 2022.
• Historically, Receivables - Net has averaged $10.4 billion across 5 years, with a median of $9.1 billion in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Net increased 3.34% — and 2025, when it jumped 61.37%.
• Eli Lilly's Receivables - Net stood at $6.9 billion in 2022, then surged by 31.82% to $9.1 billion in 2023, then advanced by 21.07% to $11.0 billion in 2024, then jumped by 61.37% to $17.8 billion in 2025, then advanced by 3.77% to $18.4 billion in 2026.
• The last three Receivables - Net figures came in at $18.4 billion (Q1 2026), $17.8 billion (Q4 2025), and $16.1 billion (Q3 2025), per Business Quant data.